Non-small-cell lung cancer

This vaccine, known as BNT116 and developed by BioNTech, targets non-small cell lung cancer (NSCLC), the most common type of lung cancer. Its aim is to eliminate cancer cells and prevent their recurrence by training the immune system to recognize and attack these cancerous cells.

The study was the result of a 682-patient trial that included participants diagnosed with non-small cell lung cancer